Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Targin | Oxycodone / naloxone | Pain, Moderate to severe and relief of opioid-induced constipation | Cancelled | |||
| Targin | Oxycodone HCI / naloxone HCI | Pain, moderate to severe and relief of opioid-induced constipation | Do not list | Complete | ||
| Tavalisse | fostamatinib | Chronic immune thrombocytopenia | Do not reimburse | Complete | ||
| Tavneos | avacopan | Antineutrophil cytoplasmic antibody-associated vasculitis | Do not reimburse | Complete | ||
| TBC | ravulizumab | Paroxysmal nocturnal hemoglobinuria. | Withdrawn | |||
| TBC | etonogestrel | Prevention of pregnancy | Withdrawn | |||
| TBC | halobetasol propionate and tazarotene | Psoriasis, moderate to severe plaque | Withdrawn | |||
| TBC | filgotinib | Arthritis, Rheumatoid | Withdrawn | |||
| TBC | Darunavir / cobicistat | HIV infection | Withdrawn | |||
| TBC | zolbetuximab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active |
Last Updated : July 28, 2024